Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy

Emilia Montagna, Marco Colleoni(European Institute of Oncology), Vincenzo Bagnardi(Cancer Research And Biostatistics), Chiara Casadio(University of Milan), Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Claudia Sangalli(Fondazione IRCCS Istituto Nazionale dei Tumori), Mauro G. Mastropasqua(University of Milan), Giuseppe Cancello, Nicole Rotmensz(European Organisation for Research and Treatment of Cancer), Andrea Sporchia(Daiichi Sankyo (United States)), Alessandra Balduzzi(European Institute of Oncology), Paolo Veronesi(Ripamonti), Viviana Galimberti, Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Alberto Luini(Institute for Experimental Endocrinology and Oncology)
Annals of Oncology
November 20, 2014
10.1093/annonc/mdu528
Cited by 54

Related Papers

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k